Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on March 11, 2016 in accordance with the provisions of the European Commission’s regulation no. 2273/2003 of December 22, 2003, also referred to as the Safe Harbor rules (company announcement no. 19 of March 11, 2016).
GN Store Nord’s share-buy-back program is applied without change, but shall going forward be subject to the European Parliament and of the Council’s regulation (EU) no 596/2014 of April 16, 2014, on market abuse and its ancillary acts.
The share buyback program has been initiated in order to reduce the company’s share capital. Under the share buyback program, which is running from March 11, 2016 and ending no later than March 13, 2017, GN intends to buy back shares for an amount of up to DKK 1,500 million.
The following transactions have been made under the program in the period February 28, 2017 –March 6, 2017:
|No. of shares||Average purchase price, DKK||Transaction Value, DKK|
|February 28, 2017||82,685||159.28||13,170,431|
|March 1, 2017||70,050||161.29||11,298,652|
|March 2, 2017||65,700||164.52||10,808,806|
|March 3, 2017||49,792||163.91||8,161,352|
|March 6, 2017||62,520||165.12||10,323,102|
|Accumulated under the program||10,068,373||142.31||1,432,822,801|
In the period from February 28, 2017 to March 6, 2017 the exercise of warrants under GN’s incentive programs have resulted in a transfer of 78,244 GN shares to key employees.
Following the above transactions GN owns a total of 14,652,781 own shares corresponding to 9.5% of the company’s total share capital. Every Tuesday, GN will announce the number and value of repurchased shares in company announcements to Nasdaq Copenhagen.
For further information please contact:
VP – Investor Relations & Treasury
GN Store Nord A/S
Tel: +45 45 75 87 16
Last updated on: 08/03/2017
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.